Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Active, not recruiting · NCT03061539 · Registry updated 2022-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2022-09-28 | NCT03061539 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| University College, London | 222 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University College London Hospital | London | United Kingdom | 32 |